Press Releases May 27, 2026 07:00 AM

G-III Apparel Group Declares Quarterly Dividend

G-III Apparel Group announces quarterly cash dividend of $0.10 per share, signaling confidence in financial stability.

By Marcus Reed GIII

G-III Apparel Group, Ltd., a global fashion leader with a diverse brand portfolio, declared a quarterly cash dividend of $0.10 per share payable to shareholders on July 8, 2026. The announcement reflects the company's ongoing commitment to returning value to investors amid its extensive licensing and retail operations in the fashion sector.

G-III Apparel Group Declares Quarterly Dividend
GIII

Key Points

  • Declared quarterly cash dividend of $0.10 per share, payable July 8, 2026.
  • Company manages a broad portfolio of over 30 brands including owned and licensed names such as DKNY, Calvin Klein, Tommy Hilfiger, and major sports leagues.
  • The company faces industry-specific challenges including changing consumer preferences, supply chain risks, reliance on foreign manufacturing, and economic conditions impacting apparel retail.

NEW YORK, May 27, 2026 (GLOBE NEWSWIRE) -- G-III Apparel Group, Ltd. (NASDAQ: GIII) today announced that its Board of Directors has declared a quarterly cash dividend of $0.10 per share. The dividend is payable on July 8, 2026 to stockholders of record on June 22, 2026.

About G-III Apparel Group, Ltd. 

G-III Apparel Group, Ltd. is a global fashion leader with expertise in design, sourcing, distribution, and marketing. The Company owns and licenses a portfolio of more than 30 preeminent brands, each differentiated by unique brand propositions, product categories, and consumer touchpoints. G-III owns ten iconic brands, including DKNY, Donna Karan, Karl Lagerfeld, Sonia Rykiel, and Vilebrequin, and licenses over 20 of the most sought-after names in global fashion, including Calvin Klein, Tommy Hilfiger, Levi’s, Halston, Champion, Converse, Cole Haan, BCBG, French Connection, Starter as well as major sports leagues such as the NFL, NBA, NHL and MLB, among others.

Statements concerning G-III's expectations regarding future events are "forward-looking statements" as that term is defined under the federal securities laws. Forward-looking statements are subject to risks, uncertainties and factors which include, but are not limited to, risks related to the reliance on licensed product, risks relating to G-III’s ability to increase revenues from sales of its other products, new acquired businesses or new license agreements as licenses for Calvin Klein and Tommy Hilfiger product expire on a staggered basis, reliance on foreign manufacturers, risks of doing business abroad, supply chain disruptions, risks related to acts of terrorism and the effects of war, the current economic and credit environment risks related to our indebtedness, the nature of the apparel industry, including changing customer demand and tastes, customer concentration, seasonality, risks of operating a retail business, risks related to G-III’s ability to reduce the losses incurred in its retail operations, customer acceptance of new products, the impact of competitive products and pricing, dependence on existing management, possible disruption from acquisitions, the impact on G-III’s business of the imposition of tariffs by the United States government and business and general economic conditions, including inflation and higher interest rates, as well as other risks detailed in G-III's filings with the Securities and Exchange Commission. G-III assumes no obligation to update the information in this release.

Investor Relations Contact:
Nick Bacchus
SVP of Investor Relations and Treasurer
[email protected]


Risks

  • Expiration of key licensing agreements for Calvin Klein and Tommy Hilfiger, which could impact revenue streams.
  • Supply chain disruptions and risks related to reliance on foreign manufacturers could affect product availability and costs.
  • General economic risks including inflation, tariffs, and changes in consumer demand could negatively affect business performance.

More from Press Releases

Eledon Announces Presentation of Updated Data from Investigator-Initiated Islet Transplant Trial of Tegoprubart in Patients with Type 1 Diabetes at American Diabetes Association (ADA) 2026 Scientific Sessions Jun 4, 2026 Satellogic to Participate in June Investor Conferences Jun 4, 2026 BIO GREEN MED SOLUTION, INC. ANNOUNCES BUSINESS COMBINATION AGREEMENT TO ACQUIRE FUTURE NRG SDN. BHD. Jun 4, 2026 SI-BONE To Present at Truist Securities 2026 MedTech Conference on June 16, 2026 Jun 4, 2026 Reliance, Inc. Announces Participation at the Wells Fargo 16th Annual Industrials & Materials Conference Jun 4, 2026